Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Positive IDEC-C2B8 phase III trial results announced

Dec. 11, 1996

Medarex bispecific antibody enters phase II in colon cancer patients

Dec. 9, 1996

Sandoz claims MAbs against Lewis group antigens for therapeutic use

Nov. 25, 1996

IDEC to present final pivotal data on IDEC-C2B8

Nov. 22, 1996

NCI sponsors clinical trials with Therion's prostate cancer vaccine

Nov. 22, 1996

First filing for Imutec's Virulizin

Nov. 21, 1996

Final phase II data presented for Biomira's therapeutic cancer vaccine

Nov. 15, 1996

Ovarian cancer vaccine enters pivotal trials in Europe

Nov. 8, 1996

Apoptosis-inducing MAb from Chugai

Nov. 8, 1996

MAb 1DT3-D disclosed for treatment of B-cell lymphoma

Oct. 25, 1996

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...